Extension in AS: Sustainability of Benefits, Safety and Tolerability

Completed · Phase 3 · Has a placebo group

Conditions studied: Spondylitis, Ankylosing

In brief

This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.

Key facts

Study ID
NCT01863732
Run by
Novartis Pharmaceuticals
People needed
274
Starts
2013-11-06
Expected to finish
2018-03-16
Last updated by the study team
2019-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.